Common Cardiovascular Risk Calculators
|
|
- Ralph Austin
- 5 years ago
- Views:
Transcription
1 PL Detail-Document # This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Common Cardiovascular Risk Calculators Risk calculators are used to target therapies toward patients who will get the most benefit from them. They can also help spare low-risk patients from adverse effects and costs of unnecessary therapy. 1 The American Heart Association states that adults 40 to 79 years of age should generally have their heart disease risk calculated every four to six years. 2,16 Risk influences decisions to institute primary prevention interventions such as daily low-dose aspirin and statins. 2,3 Use of risk calculators has not been shown to alter clinical outcomes, but it can improve prescribing and motivate patients. You can show the benefits of the lifestyle changes and drug therapies you re recommending. Consider presenting risk as percentages as well as numbers of persons per 1000 over a specific time period; some patients comprehend numbers per 1000 better. 4 Risk calculators are better at predicting events than just counting risk factors, 5 but they have limitations. For example, because age is a strong risk determinant, calculators may underestimate risk in young patients. 4,11,12 To the other extreme, risk calculators can misidentify elderly patients as targets for aggressive pharmacotherapy. 12 Most calculators can be used in older individuals, but keep in mind that those 65 years and older may have been underrepresented in the cohorts from which the calculators were derived. 13 Clinical judgment is therefore especially important in making treatment decisions in the elderly. 12 In addition, some calculators are more or less appropriate for certain populations than others (e.g., patients with diabetes). The following chart provides links to several risk calculators for North Americans, and provides information to help you choose the most appropriate calculator for a given patient. ASCVD Risk Estimator Plus A list of websites with cardiovascular risk cal culator apps for smartphones follows this chart Incorporates the original ASCVD Risk Estimator plus the 2016 Million Hearts Longitudinal ASCVD Risk Assessment Tool and new guideline recommendations. 17 Maintains the core functionality of the original ASCVD Risk Calculator; users can still calculate the patient s 10-year ASCVD risk and get guideline-based recommendations for statin therapy. Can be used to project the benefit of specific risk-lowering interventions (statins, antihypertensives, aspirin, etc), and update and track change in risk over time based on the patient's actual response to interventions. Provides recommendations from multiple ACC/AHA guidelines (e.g., blood pressure, lifestyle, etc). Initial 10-year ASCVD risk is calculated via the Pooled Cohort Equation. The updated 10-year ASCVD risk at follow-up visits and projected 10 -year ASCVD risk values are derived from the 2016 Million Hearts Longitudinal Risk Assessment Tool. Therapy advice is derived from ACC/AHA guidelines regarding cholesterol, lifestyle, and high blood pressure, and is supplemented by the Million Hearts Longitudinal Risk Assessment User Guide.
2 (PL Detail-Document #300102: Page 2 of 6) 2013 Pooled Cohort Equations Cardiovascular Risk Calculator (ASCVD Risk Calculator) (See the updated version of this calculator above [ASCVD Risk Estimator Plus].) Part of the 2013 ACC/AHA cholesterol guidelines to determine the need for statin therapy. 15 Calculates 10-year risk of atherosclerotic cardiovascular disease (myocardial infarction or stroke). Based on data from men (white and African American) and women, with or without diabetes, 40 to 79 years of age. To determine need for statin therapy, use for primary prevention only, for patients ages 40 to 75 with LDL 70 to 189 mg/dl (1.8 to 4.9 mmol/l). Individuals with LDL 190 mg/dl (5 mmol/l) or established heart disease already qualify for statin therapy. 16 Estimates lifetime risk of atherosclerotic cardiovascular disease in individuals 20 to 59 years of age. 15 May underestimate lifetime risk. 15 May overestimate risk (Mexican Americans, Asian Americans of East Asian ancestry) or underestimate risk (American Indians, Puerto Ricans, Asian Americans of South Asian ancestry). Not intended for use with statin-treated cholesterol. (If used with patients already on a statin, use pretreatment cholesterol value.) Replaces Framingham risk assessment. Framingham Coronary Heart Disease 10-year Risk Calculates 10-year risk of coronary heart disease. Based on data from whites 30 to 74 years of age without heart disease. Also validated in African Americans and Hispanic women. May over- or underestimate risk in other ethnic groups. 7 Less precise in patients under 30 or over 65 years of age, and in patients with diabetes, severe hypertension, or left ventricular hypertrophy. 5 Framingham General Cardiovascular Disease 10-year Risk Calculates 10-year risk of cardiovascular disease (i.e., coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, transient ischemic attack, peripheral artery disease, heart failure). Based on data from predominantly whites 30 to 74 years of age without CVD at baseline. 14 Separate calculators for men and women.
3 (PL Detail-Document #300102: Page 3 of 6) National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) risk assessment tool based on Framingham Heart Study Reynolds Risk score American Diabetes Association s Diabetes My Health Advisor risk assessment tool S.html?loc=dorg-mha Calculates 10-year risk for myocardial infarction and coronary death. For adults 20 years and older without heart disease or diabetes. Not recommended for patients with diabetes because ATP III considered diabetes a coronary disease equivalent. 5 However, current thinking is that not all patients with diabetes are high-risk. 6 Omits family history. Classifies 15% of adults into different risk groups than Framingham (10% higher risk, 5% lower risk). 8 Calculates 10-year risk of heart attack, stroke, or other major heart disease. For healthy patients without diabetes 45 to 80 years of age. Separate calculators for women and men. Based on data from Women s Health Study and Physicians Health Study II. 1 Includes family history and hs-crp. Reclassifies 30% of intermediate risk women and 20.2% of intermediate risk men into lower or higher risk categories vs Framingham. 1 Not validated in Canadian population. 9 Calculates 10-year risk of heart attack or stroke and 8-year risk of diabetes. Also calculates risk of diabetes complications. 10 Can be used for people with or without diabetes. Can be used for people with or without cardiovascular disease. Patients can use on their own. Designed to show how changes in lifestyle or medication can affect risk. Good choice if contemplating aspirin for primary prevention in patients with diabetes. 6 ARIC CHD Risk Calculator RC1.html Calculates 10-year risk of heart attack or coronary heart disease risk in adults. Can be used for people with or without diabetes. For people 45 to 65 years of age. Good choice if contemplating aspirin for primary prevention in patients with diabetes. 6
4 (PL Detail-Document #300102: Page 4 of 6) UKPDS Risk Engine Diabetes Canada tool for identifying diabetes patients who require vascular protective medication Based on data from the UK Prospective Diabetes Study. For patients with diabetes without known heart disease. Calculates 10-year risk estimates for fatal and nonfatal coronary heart disease, fatal coronary heart disease, fatal and nonfatal stroke, and fatal stroke. Good choice if contemplating aspirin for primary prevention in patients with diabetes. 6 For patients with diabetes. Not a quantitative tool; identifies high-risk patients for whom certain pharmacologic interventions are recommended (e.g., ACEI, ARB, statin). n/riskassessment McGill Cardiovascular Health Improvement Program for assessing a patient s Cardiovascular Age (Canada) Use to explain the patient s cardiovascular risk to them and how it can be improved. Can be used to show patients how risk improves with treatment. Some Cardiovascular Risk Calculator Apps for Smartphones Statcoder ( provides 2013 Pooled Cohort Equations CV Risk Calculator, ATP III, Framingham, and Reynolds for iphone, ipod Touch, and ipad (free). Calculate ( includes Framingham and Reynolds for iphone, ipod Touch, ipad, Blackberry, and Android (free). Archimedes 360 ( provides over 200 medical calculators including Framingham and ATP III for iphone, ipod Touch, ipad, Blackberry, Android, and Windows Mobile Smartphone (less than $25) Pooled Cohort Equations CV Risk Calculator ( for iphone, ipod Touch, ipad (free). ClinCalc ( includes a number of online calculators, as well as 2013 Pooled Cohort Equations CV Risk Calculator for iphone/ipad and Android (free). ScyMed ( has 2013 Pooled Cohort Equations CV Risk Calculator for Android ($1.00).
5 (PL Detail-Document #300102: Page 5 of 6)
6 (PL Detail-Document #300102: Page 6 of 6) Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication. Project Leader in preparation of this PL Detail- Document: Melanie Cupp, Pharm.D., BCPS (Original November 2010); Stacy A. Hester, R.Ph., BCPS, Assistant Editor (January 2014 update); last modified May References 1. Sisson E, Van Tassell BW. Dyslipidemias: updates and new controversies. In: Richardson M, Chant C, Cheng JWM, et al., editors. Pharmacotherapy selfassessment program, 7 th ed. Cardiology. Lenexa, KS: American College of Clinical Pharmacy; p Pearson TA, Blair SN, Daniels SR, et al. American Heart Association Science Advisory and Coordinating Committee. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation 2002;106: National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. September ll.pdf. (Accessed December 3, 2013). 4. Viera AJ, Sheridan SL. Global risk of coronary heart disease: assessment and application. Am Fam Physician 2010;82: Sheridan S, Pignone M, Mulrow C. Framinghambased tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003;18: Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010;121: D Agostino RB, Grundy S, Sullivan LM, et al. Validation of the Framingham Coronary Heart Disease Prediction Scores. JAMA 2001;286: Gordon WJ, Polansky JM, Boscardin WJ, et al. Coronary risk assessment by point-based vs equation-based Framingham models: significant implications for clinical care. J Gen Intern Med 2010;25: Genest J, McPherson R, Frohlich J, et al Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol 2009;25: Stern M, Williams K, Eddy D, Kahn R. Validation of prediction of diabetes by the Archimedes model and comparison with other predicting models. Diabetes Care 2008;31: Berry JD, Lloyd-Jones DM, Garside DB, Greenland P. Framingham risk score and prediction of coronary heart disease death in young men. Am Heart J 2007;154: Grundy SM, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiplerisk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999;100: Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. J Am Coll Cardiol 2009;54: D Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008;117: Goff DC Jr, Lloyd-Jones DM, Bennett G, et al ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 Nov 12 [Epub ahead of print];doi: /01.cir /- /DC Stone NJ, Robinson J, Lichtenstein AH, et al ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013 Nov 12 [Epub ahead of print];doi: /01.cir a. 17. American College of Cardiology. ASCVD Risk Calculator Plus. practice-support/mobile-resources/features/2013- prevention-guidelines-ascvd-risk-estimator. (Accessed April 17, 2018).
7 (PL Detail-Document #300102: Page 7 of 6) Cite this document as follows: PL Detail-Document, Common Cardiovascular Risk Calculators. Pharmacist s Letter/Prescriber s Letter. January Evidence and Recommendations You Can Trust 3120 West March Lane, Stockton, CA ~ TEL (209) ~ FAX (209) Copyright 2014 by Therapeutic Research Center Subscribers to the Letter can get PL Detail-Documents, like this one, on any topic covered in any issue by going to or
Cardiovascular Risk in Patients with Diabetes
PL Detail-Document #270516 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER May 2011 Cardiovascular Risk
More informationAcute Coronary Syndromes (ACS)
Sally A. Arif, Pharm.D., BCPS (AQ Cardiology) Assistant Professor of Pharmacy Practice Midwestern University, Chicago College of Pharmacy Cardiology Clinical Specialist, Rush University Medical Center
More informationAtherosclerotic Disease Risk Score
Atherosclerotic Disease Risk Score Kavita Sharma, MD, FACC Diplomate, American Board of Clinical Lipidology Director of Prevention, Cardiac Rehabilitation and the Lipid Management Clinics September 16,
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationAssessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients. Copyright. Not for Sale or Commercial Distribution
CLINICAL Viewpoint Assessing Cardiovascular Risk to Optimally Stratify Low- and Moderate- Risk Patients Copyright Not for Sale or Commercial Distribution By Ruth McPherson, MD, PhD, FRCPC Unauthorised
More informationThe recently released American College of Cardiology
Data Report Atherosclerotic Cardiovascular Disease Prevention A Comparison Between the Third Adult Treatment Panel and the New 2013 Treatment of Blood Cholesterol Guidelines Andre R.M. Paixao, MD; Colby
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationAspirin for the Prevention of Cardiovascular Disease
Detail-Document #250601 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2009 ~ Volume 25 ~ Number 250601 Aspirin for the Prevention of Cardiovascular
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More information9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.
UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationAchieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care
Achieving Cholesterol Management Goals: Identifying Clinician-Centered Challenges to Optimal Patient Care Purpose Explore the adherence rates to cholesterol treatment targets among patients who seek care
More informationSupplementary Online Content
Supplementary Online Content Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationSepsis and Septic Shock: New Definitions for Adults
PL Detail-Document #320424 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2016 Sepsis and Septic
More informationEzetimibe s Role in Cardiovascular Risk Reduction
PL Detail-Document #310101 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2015 Ezetimibe s Role
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationUpdate on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines
Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease
More informationNew Guidelines in Dyslipidemia Management
The Third IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2017 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationApplication of New Cholesterol Guidelines to a Population-Based Sample
The new england journal of medicine original article Application of New Cholesterol to a Population-Based Sample Michael J. Pencina, Ph.D., Ann Marie Navar-Boggan, M.D., Ph.D., Ralph B. D Agostino, Sr.,
More informationThe use of statins for primary prevention and evidencebased
Impact of Statin Guidelines on Statin Utilization and Costs in an Employer-Based Primary Care Clinic Holly E. Gurgle, PharmD, BCACP, CDE; Marisa B. Schauerhamer, PharmD; Simón A. Rodriguez, PharmD; and
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationCalculating Risk for Primary Prevention of Cardiovascular Disease (CVD)
Calculating Risk for Primary Prevention of Cardiovascular Disease (CVD) 2. Welcome by Stacey Sheridan, MD, MPH Hello. My name is Stacey Sheridan, and I m here as your partner in Heart Health Now. The North
More informationCurrent Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD
Current Cholesterol Guidelines and Treatment of Residual Risk J. Peter Oettgen, MD Associate Professor of Medicine Harvard Medical School Director, Preventive Cardiology Beth Israel Deaconess Medical Center
More informationHYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016
HYPERLIPIDEMIA IN THE OLDER POPULATION NICOLE SLATER, PHARMD, BCACP AUBURN UNIVERSITY, HARRISON SCHOOL OF PHARMACY JULY 16, 2016 NOTHING TO DISCLOSE I, Nicole Slater, have no actual or potential conflict
More informationSupplementary Online Content
Supplementary Online Content Pokharel Y, Tang F, Jones PG, et al. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in cardiology practices
More informationTHE 2013 ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL
THE 2013 ACC/AHA GUIDELINES ON THE TREATMENT OF BLOOD CHOLESTEROL Anne Carol Goldberg, MD, FACP, FAHA, FNLA Associate Professor of Medicine Washington University School of Medicine National Lipid Association
More informationThe Art of Cardiovascular Risk Assessment
The Art of Cardiovascular Risk Assessment Laurence S. Sperling, M.D., FACC, FACP,FAHA, FASPC Professor of Medicine (Cardiology) Professor of Global Health Director- Center for Heart Disease Prevention
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationReview current guideline recommendations for lipid-lowering therapy
Breakout Session #3 New Paradigms in the Management of Dyslipidemia Review current guideline recommendations for lipid-lowering therapy Dr Meral KAYIKCIOGLU Ege University Medical School, Cardiology Dept,
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2062-8 Program Prior Authorization/Medical Necessity Medication Praluent (alirocumab) P&T Approval Date 5/2015, 8/2015, 9/2015,
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationObservations on US CVD Prevention Guidelines. Donald M. Lloyd-Jones, MD ScM FACC FAHA
Observations on US CVD Prevention Guidelines Donald M. Lloyd-Jones, MD ScM FACC FAHA What are Guidelines? Evidence Base for Guidelines Tricoci, JAMA 2009 Evidence Base for Guidelines Tricoci, JAMA 2009
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationDiabetes Care 31: , 2008
Cardiovascular and Metabolic Risk O R I G I N A L A R T I C L E Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S. KHIET C. HOANG, MD HELI GHANDEHARI VICTOR
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationSpeaker Disclosure. Pharmacist Objectives. Path to New Hypertension (HTN) Guidelines. Overview of New HTN Guidelines 8/21/2014
Speaker Disclosure Erica Pearce, Pharm.D. declares no conflicts of interest, real or apparent, and no financial interests in any company, product, or service mentioned in this program, including grants,
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationJOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 64, NO. 10, 2014 ª 2014 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN /$36.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY VOL. 64, NO. 1, 214 ª 214 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 735-197/$36. PUBLISHED BY ELSEVIER INC. http://dx.doi.org/1.116/j.jacc.214.6.1186
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2063-8 Program Prior Authorization/Medical Necessity Medication Repatha (evolocumab) P&T Approval Date 5/2015, 9/2015, 11/2015,
More informationPrevention of Heart Disease: The New Guidelines
Prevention of Heart Disease: The New Guidelines Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California San Francisco May 18 th 2015
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationCVD risk calculation
CVD risk calculation Cardiovascular disease (CVD) is the most common cause of death in Alberta, accounting for nearly one third (31%) of the overall deaths (1). The majority (90%) of the CVD cases are
More informationUnderstanding US Lipid Guidelines-2013:
Presentation to NLA Symposium: May 3 2014 Understanding US Lipid Guidelines-2013: Neil J. Stone MD, MACP, FACC Bonow Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Il
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationGlobal Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic. Syndrome. and Nathan D. Wong, PhD, MPH
Diabetes Care Publish Ahead of Print, published online April 1, 2008 Global Coronary Heart Disease Risk Assessment of U.S. Persons With the Metabolic Syndrome Khiet C. Hoang MD, Heli Ghandehari, BS, Victor
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationTreatment of Hypertension
This Clinical Resource gives subscribers additional insight related to the Recommendations published in January 2018 ~ Resource #340101 Treatment of Hypertension In 2013, the JNC 8 panel released recommendations
More informationQuality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care
Quality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationObjectives. Background. Background. Estimating ASCVD Risk. ASCVD Major Risk Factors 2/20/2018
Objectives Discuss risk stratification and non-pharmacologic means of reducing primary cardiovascular risk Compare and contrast pharmacologic agents for the prevention of cardiovascular disease Kevin T.
More informationPrimary prevention of Cardiovascular Diseases: Differences between European and United States Guidelines
18 MEDICINSKI GLASNIK / str. 18-23 Vojislav Giga 1,2, Marija Petrović 1 Primary prevention of Cardiovascular Diseases: Differences between European and United States Guidelines Abstract: European Society
More informationManageMent Review. Boback Ziaeian, MD, 1,2 John Dinkler, MD, MPH, 1,2 Karol Watson, MD, PhD 1,3 1
ManageMent Review Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy
More informationClinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk
1/5 MENU ORIGINAL RESEARCH 3 JULY 2018 Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk Article, Author, and Disclosure Information PREV
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationAspirin Dose for Cardiovascular Indications
PL Detail-Document #280901 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER September 2012 Aspirin Dose
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More information8/15/2018. Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome. Metabolic Syndrome.
Promoting Education, Referral and Treatment for Patients Presenting with Metabolic Syndrome Diagnostic Criteria (3/5) Metabolic Syndrome Key Facts JAN BRIONES DNP, APRN, CNP FAMILY NURSE PRACTITIONER Abdominal
More information2.3 CONTACT HOURS. Managing. By Kristine Anne Scordo, PhD, RN, ACNP-BC, FAANP
2.3 CONTACT HOURS 2.3 CONTACT HOURS Managing hyperlipidemia The updated cholesterol treatment guidelines Abstract: The ACC/AHA 2013 cholesterol treatment guidelines focus on lowering the risk of heart
More informationPrevention Updates and Paradigm Shifts
Prevention Updates and Paradigm Shifts Andrew Freeman, MD, FACC Director of Clinical Cardiology and Operations National Jewish Health Assistant Professor of Medicine National Jewish Health and University
More information2013 Lipid Guidelines Practical Approach. Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS
2013 Lipid Guidelines Practical Approach Edward Goldenberg, MD FACC,FACP, FNLA Medical Director of Cardiovascular Prevention CCHS EVIDENCE BASED MEDICINE Case #1 - LB 42 yo Asian/American female who was
More informationImplementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines
Summary Implementing new Dyslipidemia Guidelines Implementation of CV Risk and Dyslipidemia Guidelines Ronald D. Scott, MD Regional KPSC CVD Co-Lead Family Medicine and Lipidology, WLA ASCVD (Atherosclerotic
More informationDisclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.
Disclosures Prevention of Heart Disease: The New Guidelines No relevant disclosures Nisha I. Parikh MD MPH Assistant Professor of Medicine Division of Cardiology Department of Medicine University of California
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More information4 th and Goal To Go How Low Should We Go? :
4 th and Goal To Go How Low Should We Go? : Evaluating New Lipid Lowering Therapies Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More information2/10/2016. Perspectives on the 2013 ACC/AHA Cholesterol Guidelines. Disclosures. ATP-III Update 2004
Perspectives on the 2013 ACC/AHA Cholesterol Guidelines Donald M. Lloyd-Jones, MD ScM Senior Associate Dean Chair and Professor of Preventive Medicine Northwestern Feinberg School of Medicine Disclosures
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationNotes Indicate to the group that this patient will be the focus of today s case discussion.
1 Indicate to the group that this patient will be the focus of today s case discussion. Read out the case authors and their disclosure information. Instructions Fill out prior to the meeting and disclose
More informationPCSK9 Agents Drug Class Prior Authorization Protocol
PCSK9 Agents Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review of medical
More informationAnalyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins. Peter Thorne
Abstract Analyzing Coronary Heart Disease Risk Factors and Proper Clinical Prescription of Statins Peter Thorne A sample of adults participating in the first 7 months of visit 5 of the Atherosclerosis
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationCVD Prevention, Who to Consider
Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..
More informationStatins after 80 years old. Pros/Cons symposium. 13 th EUGMS Congress Nice Sept 2017
Statins after 80 years old Pros/Cons symposium 13 th EUGMS Congress Nice 20-22 Sept 2017 Athanasios Benetos Conflict of interest: None The Statinissean War Two fearless fighters Athanasios the Athenian
More informationCompounding KI for Radiation Exposure
PL Detail-Document #270323 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2011 Compounding KI for
More informationHYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS
HYPERTENSION MANAGEMENT IN ELDERLY POPULATIONS Michael J. Scalese, PharmD, BCPS, CACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 14, 2018 DISCLOSURE/CONFLICT OF INTEREST
More informationSanger Heart & Vascular Institute Symposium 2015
Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute
More informationModule 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension
Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationAssessing atherosclerotic risk for long term preventive treatment
Assessing atherosclerotic risk for long term preventive treatment Donald A. Smith, MD, MPH Endocrinologist, Clinical Lipidologist Associate Professor of Medicine and Preventive Medicine Icahn School of
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationLipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice
Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice Vera Bittner, MD, MSPH Professor of Medicine Section Head, Preventive Cardiology Medical Director, Cardiac Rehabilitation
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationThe Pharmacists Role in Lipid Management
The Pharmacists Role in Lipid Management Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant Clinical Assistant Professor, Univ. of Maryland Learning Objectives 1. ENHANCE your understanding
More informationEstimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies
AHA/ACC Special Report: The Million Hearts Longitudinal ASCVD Risk Assessment Tool Page 1 AHA/ACC Special Report Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among
More information